In probably a new drug scandal from China, self-proclaimed employees alleged that a Fosun unit faked production and testing records.
It was a U.S. drugmaker that first alerted the FDA that a valsartan API from a Chinese ingredient maker contained a a dangerous impurity.
Ascletis' stock price slips 44% in a month on HKEX; Zai Lab cans a dermatitis drug licensed from GSK; WuXi names CFO a co-CEO; and more.
China has withheld shipments of the H7N9 strain to the U.S. for research, according to The New York Times.
The Nasdaq-listed plasma specialist is raising $590 million via share issuance to fund business expansion plans and strategic acquisitions.
Opdivo is priced in China at half its U.S. cost; Novartis names new chief for scandal-hit Korea unit; GSK's Indian consumer unit attracts new buyers.
China is criminally prosecuting people and companies tied to Juxin Biotech where a plant explosion killed 10 people.
Korean biotech ViroMed has acquired a GMP-ready facility in San Diego, California, as its gene therapy nears the completion of phase 3 trials.
With Bristol-Myers' Opdivo sticker, the benchmark for prices of future immuno-oncology therapies in China is here.
An ongoing criminal trial in Korea alleges that Novartis used medical journals to funnel kickbacks to doctors.